CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Niraparib

尼拉帕尼 杂质对照品Niraparib Impurities

38 个杂质条目38 impurity entries

本页汇总 尼拉帕尼 的 38 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 38 impurity reference standards of Niraparib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 尼拉帕尼(Niraparib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance
    Chirality · 2026 · Kondaveti PK et al.  ·  PMID 42304726  ·  DOI
  2. 杂质研究Impurity studiesMassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
    ACS omega · 2023 · Bonciarelli S et al.  ·  PMID 36844573  ·  DOI
  3. 分析方法Analytical MethodsLC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
    Pharmaceutics · 2023 · Canil G et al.  ·  PMID 37242766  ·  DOI
  4. 分析方法Analytical MethodsQuantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS
    Biomedical chromatography : BMC · 2020 · Krens SD et al.  ·  PMID 31758580  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisRealization of a Manufacturing-Scale Synthesis of Niraparib Using an Evolved Transaminase
    Chembiochem : a European journal of chemical biology · 2026 · Jones REH et al.  ·  PMID 42801751  ·  DOI

尼拉帕尼 —— 原料药与杂质对照品Niraparib — drug substance & impurities

共 39 个条目(含原料药本体)39 items incl. the drug substance
Niraparib structure
原料药 APIAPI
尼拉帕尼Niraparib
Niraparib
CAS No.1038915-60-4
Chemical FormulaC19H20N4O
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib p-Toluenesulfonate Monohydrate structure
—
对甲苯磺酸尼拉帕尼一水合物Niraparib p-Toluenesulfonate Monohydrate
Niraparib p-Toluenesulfonate Monohydrate
CAS No.1613220-15-7
Chemical FormulaC19H20N4O·C7H8O3S·H2O
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 1 structure
1
尼拉帕尼杂质1Niraparib Impurity 1
Niraparib Impurity 1
CAS No.1038915-58-0
Chemical FormulaC19H20N4O
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 3 structure
3
尼拉帕尼杂质3Niraparib Impurity 3
Niraparib Impurity 3
CAS No.443882-99-3
Chemical FormulaC13H9ClFNO3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 4 structure
4
尼拉帕尼杂质4Niraparib Impurity 4
Niraparib Impurity 4
CAS No.138229-59-1
Chemical FormulaC9H7NO5
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 5 structure
5
尼拉帕尼杂质5Niraparib Impurity 5
Niraparib Impurity 5
CAS No.1263284-59-8
Chemical FormulaC16H24N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 6 structure
6
尼拉帕尼杂质6Niraparib Impurity 6
Niraparib Impurity 6
CAS No.1476776-55-2
Chemical FormulaC16H22BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 7 structure
7
尼拉帕尼杂质7Niraparib Impurity 7
Niraparib Impurity 7
CAS No.769944-73-2
Chemical FormulaC16H22BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 8 structure
8
尼拉帕尼杂质8Niraparib Impurity 8
Niraparib Impurity 8
CAS No.1476776-97-2
Chemical FormulaC23H28N4O
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 9 structure
9
尼拉帕尼杂质9Niraparib Impurity 9
Niraparib Impurity 9
CAS No.1476776-84-7
Chemical FormulaC28H36N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 10 structure
10
尼拉帕尼杂质10Niraparib Impurity 10
Niraparib Impurity 10
CAS No.2308483-85-2
Chemical FormulaC19H22N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 11 structure
11
尼拉帕尼杂质11Niraparib Impurity 11
Niraparib Impurity 11
CAS No.1476777-06-6
Chemical FormulaC19H19N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 15 structure
15
尼拉帕尼杂质15Niraparib Impurity 15
Niraparib Impurity 15
CAS No.2244064-26-2
Chemical FormulaC16H22BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 16 structure
16
尼拉帕尼杂质16Niraparib Impurity 16
Niraparib Impurity 16
CAS No.1038915-75-1
Chemical FormulaC19H20N4O
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 20 structure
20
尼拉帕尼杂质20Niraparib Impurity 20
Niraparib Impurity 20
CAS No.68109-89-7
Chemical FormulaC12H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 21 structure
21
尼拉帕尼杂质21Niraparib Impurity 21
Niraparib Impurity 21
CAS No.1038916-11-8
Chemical FormulaC24H28N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 22 structure
22
尼拉帕尼杂质22Niraparib Impurity 22
Niraparib Impurity 22
CAS No.2244220-34-4
Chemical FormulaC20H21N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 25 structure
25
尼拉帕尼杂质25Niraparib Impurity 25
Niraparib Impurity 25
CAS No.2381228-27-7
Chemical FormulaC21H32N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 26 structure
26
尼拉帕尼杂质26Niraparib Impurity 26
Niraparib Impurity 26
CAS No.1369926-38-4
Chemical FormulaC8H4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 27 structure
27
尼拉帕尼杂质27Niraparib Impurity 27
Niraparib Impurity 27
CAS No.1289162-62-4
Chemical FormulaC8H6N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 28 structure
28
尼拉帕尼杂质28Niraparib Impurity 28
Niraparib Impurity 28
CAS No.1289174-44-2
Chemical FormulaC8H5NO5
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 29 structure
29
尼拉帕尼杂质29Niraparib Impurity 29
Niraparib Impurity 29
CAS No.50424-93-6
Chemical FormulaC8H6ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 30 structure
30
尼拉帕尼杂质30Niraparib Impurity 30
Niraparib Impurity 30
CAS No.2091464-38-7
Chemical FormulaC8H6N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 31 structure
31
尼拉帕尼杂质31Niraparib Impurity 31
Niraparib Impurity 31
CAS No.1196713-21-9
Chemical FormulaC11H16N2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 32 structure
32
尼拉帕尼杂质32Niraparib Impurity 32
Niraparib Impurity 32
CAS No.1334823-70-9
Chemical FormulaC11H16N2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 33 structure
33
尼拉帕尼杂质33Niraparib Impurity 33
Niraparib Impurity 33
CAS No.2308483-83-0
Chemical FormulaC19H20N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 34 structure
34
尼拉帕尼杂质34Niraparib Impurity 34
Niraparib Impurity 34
CAS No.946076-73-9
Chemical FormulaC11H12BrNO
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 35 structure
35
尼拉帕尼杂质35Niraparib Impurity 35
Niraparib Impurity 35
CAS No.1476776-44-9
Chemical FormulaC11H12BrNO
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 36 (Mixture of E/Z-isomers) structure
36
尼拉帕尼杂质36 (混合E/Z构型)Niraparib Impurity 36 (Mixture of E/Z-isomers)
Niraparib Impurity 36 (Mixture of E/Z-isomers)
CAS No.2941555-80-0
Chemical FormulaC11H12N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 37 structure
37
尼拉帕尼杂质37Niraparib Impurity 37
Niraparib Impurity 37
CAS No.1203686-41-2
Chemical FormulaC16H22BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 38 structure
38
尼拉帕尼杂质38Niraparib Impurity 38
Niraparib Impurity 38
CAS No.1203683-54-8
Chemical FormulaC16H22BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 39 Monomer structure
39
尼拉帕尼杂质39 单体Niraparib Impurity 39 Monomer
Niraparib Impurity 39 Monomer
CAS No.1336754-69-8
Chemical FormulaC11H14BrN
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 39 structure
39
尼拉帕尼杂质39Niraparib Impurity 39
Niraparib Impurity 39
CAS No.2409590-07-2
Chemical FormulaC11H14BrN·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 41 structure
41
尼拉帕尼杂质41Niraparib Impurity 41
Niraparib Impurity 41
CAS No.1476776-92-7
Chemical FormulaC28H36N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 42 structure
42
尼拉帕尼杂质42Niraparib Impurity 42
Niraparib Impurity 42
CAS No.1476776-96-1
Chemical FormulaC25H28N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 48 (N-Nitroso Niraparib Impurity 1) structure
48
尼拉帕尼杂质48 (N-亚硝基尼拉帕尼杂质1)Niraparib Impurity 48 (N-Nitroso Niraparib Impurity 1)
Niraparib Impurity 48 (N-Nitroso Niraparib Impurity 1)
CAS No.3078588-17-4
Chemical FormulaC19H19N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 49 structure
49
尼拉帕尼杂质49Niraparib Impurity 49
Niraparib Impurity 49
CAS No.1203682-58-9
Chemical FormulaC11H14BrN
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 50 structure
50
尼拉帕尼杂质50Niraparib Impurity 50
Niraparib Impurity 50
CAS No.1260646-65-8
Chemical FormulaC11H13Br2N
Purity>95%询价On request
10mg25mg50mg100mg
Niraparib Impurity 51 structure
51
尼拉帕尼杂质51Niraparib Impurity 51
Niraparib Impurity 51
CAS No.1391135-51-5
Chemical FormulaC11H13Br2N
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

尼拉帕尼 —— 研究文献与合成路线Niraparib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 尼拉帕尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Niraparib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
    Bonciarelli S, Desantis J, Cerquiglini S, et al. · ACS omega · 2023 · 被引 2cited 2
  2. A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance
    Kondaveti PK, Douglas P, Raghunadh A, et al. · Chirality · 2026

合成路线文献Synthetic-route papers

  1. Realization of a Manufacturing-Scale Synthesis of Niraparib Using an Evolved Transaminase
    Jones REH, Chang S, Desai N, et al. · Chembiochem : a European journal of chemical biology · 2026
  2. Synthesis and bioevaluation of a new <sup>68</sup>Ga-labelled niraparib derivative that targets PARP-1 for tumour imaging
    Wang Q, Li Z, Jiang Y, et al. · Bioorganic chemistry · 2025

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

尼拉帕尼 杂质谱研究要点Niraparib — impurity profiling notes

下面这些是拿到 尼拉帕尼 的 39 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 39 impurity entries for Niraparib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances